Charles Schwab
CRSP icon

Charles Schwab’s CRISPR Therapeutics CRSP Stock Holding History

Charles Schwab’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.7M Buy
1,057,837
+18,488
+2% +$974K 0.01% 1149
2026
Q1 		$49.4M Buy
1,039,349
+9,167
+0.9% +$484K 0.01% 1160
2025
Q4 		$54M Buy
1,030,182
+44,412
+5% +$2.66M 0.01% 1105
2025
Q3 		$63.9M Buy
985,770
+52,566
+6% +$3.02M 0.01% 992
2025
Q2 		$45.4M Buy
933,204
+219,665
+31% +$8.5M 0.01% 1164
2025
Q1 		$24.3M Sell
713,539
-9,493
-1% -$402K ﹤0.01% 1528
2024
Q4 		$28.5M Sell
723,032
-1,209
-0.2% -$57.1K 0.01% 1492
2024
Q3 		$34M Buy
724,241
+6,635
+0.9% +$337K 0.01% 1363
2024
Q2 		$38.8M Buy
717,606
+48,414
+7% +$2.8M 0.01% 1248
2024
Q1 		$45.6M Buy
669,192
+16,169
+2% +$1.16M 0.01% 1108
2023
Q4 		$40.9M Buy
653,023
+15,085
+2% +$834K 0.01% 1134
2023
Q3 		$29M Sell
637,938
-8,773
-1% -$453K 0.01% 1250
2023
Q2 		$36.3M Buy
646,711
+5,934
+0.9% +$337K 0.01% 1096
2023
Q1 		$29M Sell
640,777
-317
-0% -$15.4K 0.01% 1194
2022
Q4 		$26.1M Buy
641,094
+18,976
+3% +$1.01M 0.01% 1248
2022
Q3 		$40.7M Buy
622,118
+273,995
+79% +$19.9M 0.01% 883
2022
Q2 		$21.2M Sell
348,123
-6,680
-2% -$393K 0.01% 1369
2022
Q1 		$22.3M Buy
+354,803
New +$22.3M 0.01% 1460

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Charles Schwab's CRSP Position: Q2 2026 in Review

Charles Schwab increased its CRISPR Therapeutics (CRSP) stake by 1.8% in Q2 2026, buying an estimated $974K and bringing the position to 1,057,837 shares worth $57.7M. The position accounts for 0.01% of the portfolio, ranked #1149.

Charles Schwab first reported a position in CRSP in Q1 2022 and has held it in 18 quarters since. The position peaked at $63.9M in Q3 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Charles Schwab held 1,057,837 shares of CRISPR Therapeutics worth $57.7M as of Q2 2026.
  • Charles Schwab bought 18,488 CRISPR Therapeutics shares in Q2 2026, an estimated $974K.
  • CRISPR Therapeutics made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1149 holding.
  • Charles Schwab first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Charles Schwab's CRISPR Therapeutics position peaked at $63.9M in Q3 2025.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.